People · Operator
Named in public records as an officer, director or promoter · active 2009–2024 · Pharmaceuticals, Medical Devices, Biotech / Pharma, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Lycera Corp | — | Pharmaceuticals | Series B | $85.7M | $1.0B | 2009 |
| Celsee Diagnostics, Inc. | — | Medical Devices | Series B | $40.5M | $135.3M | 2012 |
| Ten Bay Bio, Inc. | — | Biotech / Pharma | Series A | $11.5M | $58.4M | 2024 |
| Solulink Inc | — | Biotechnology | Seed | $3.3M | $19.1M | 2013 |
Tim Mayleben at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Tim Mayleben on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| John Miller | 2 | 27 |
| TIMOTHY MAYLEBEN | 2 | 3 |
| Walter Young, Jr. | 2 | 2 |
| Steven Gillis | 1 | 23 |
| Kristina Burow | 1 | 16 |
| Nina Kjellson | 1 | 11 |
| Jack Ball | 1 | 10 |
| David Schwartz | 1 | 7 |
| PAUL SEKHRI | 1 | 7 |
| Casey Cunningham | 1 | 7 |
| Gregg Fergus | 1 | 5 |
| Paul Weiss | 1 | 5 |
| Roger Newton | 1 | 4 |
| Kathleen M. Metters | 1 | 4 |
| Michael Steinmetz | 1 | 4 |
| Timothy M. Mayleben | 1 | 4 |
| Michael Hayden | 1 | 4 |
| Jeffrey Leiden | 1 | 4 |
| Gary D. Glick | 1 | 3 |
| Mark Horne | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.